Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis
Sign Up to like & getrecommendations! Published in 2025 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2025.2470733
Abstract: Abstract Objective Letermovir (LET) is effective for preventing cytomegalovirus infection (CMVi) and CMV disease in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, clinically significant (cs)-CMVi can occur after LET cessation. We retrospectively evaluated… read more here.
Keywords: cmvi; allo hsct; late onset; burden late ... See more keywords